Search for: "Ranbaxy Laboratories Limited"
Results 21 - 40
of 47
Sorted by Relevance
|
Sort by Date
18 Aug 2010, 12:19 am
Ranbaxy Laboratories Ltd. et al. [read post]
13 May 2010, 4:58 pm
Ranbaxy Inc. et al. [read post]
10 Oct 2011, 10:00 am
Teva, Ranbaxy Pharmaceuticals, Inc., Mylan Pharmaceutical Inc., and Barr Laboratories, Inc. - which Teva now owns - all have taken steps toward entering the market, and all are eligible to seek a 180-day marketing exclusivity provided under federal law. [read post]
3 Jun 2009, 8:55 pm
The Eastern District of Virginia construed the claims and granted-in-part Lupin's motion for summary judgment of noninfringement, In the Illinois action, Abbott sued Sandoz (and Sandoz GmbH, Teva Pharmaceuticals, Ranbaxy Laboratories, Par Pharmaceutical) for infringement after they wanted to market generic versions of Omnicef. [read post]
18 Sep 2013, 1:51 am
Nor is this overseas imposition of U.S. regulation on Non-U.S. companies limited just to companies in the financial sector. [read post]
20 May 2009, 5:18 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: ACLU, PUBPAT and others file lawsuit challenging constitutionality of patents on human genes associated with breast and ovarian cancer: Association for Molecular Pathology et al v USPTO et al (Patent Baristas) (Ars Technica) (Patently-O) (IP Watchdog) (The Prior Art) (Patent Docs) (Patents4Life) Omnicef (Cefdinir) - US: CAFC rules en banc:… [read post]
2 Jul 2017, 12:52 am
However, where the specification sets out an explicit “promise”, utility will be measured against that promise: Consolboard; Pfizer v.Canada (Minister of Health), 2008 FCA 108, [2009] 1 F.C.R. 253 (Ranbaxy). [read post]
1 Jul 2017, 9:39 am
However, where the specification sets out an explicit “promise”, utility will be measured against that promise: Consolboard; Pfizer v.Canada (Minister of Health), 2008 FCA 108, [2009] 1 F.C.R. 253 (Ranbaxy). [read post]
27 Feb 2009, 5:00 am
(Patent Docs) (Afro-IP) Access to drugs: Gilead’s non exclusive model (Afro-IP) (GenericsWeb) India: Drug patent linkage is subject of court case, dispute in India (Intellectual Property Watch) India: Ranbaxy’s manufacturing woes deepen; USFDA invokes Application Integrity Policy against Paonta Sahib facility (FDA Law Blog) UK patent practice on human embryos post-WARF (IPKat) US: Congressman Waxman tells GPhA meeting that Hatch-Waxman model will work for follow-on… [read post]
17 Nov 2010, 1:48 am
PhotoCure (FDA Law Blog) US: Clinical trial requirements are top issue at FDA hearings on biosimilars (Patent Docs) Products Allegra (Fenofexadine, Psuedoephedrine) – US: Impax Laboratories receives final FDA approval for generic Allegra-D 60mg/120mg tablets (SmartBrief) Allegra (Fexofenadine) – US: Sanofi-Aventis, Aventisub, Carderm file patent infringement complaint against Aurolife, Aurobindo following Para IV certification (Patent Docs) Boniva (Ibandronate) – US: Roche… [read post]
4 Apr 2008, 1:00 am
- Counterfeit cash flooding the market: (Afro-IP), Debranded fakes for Liberia: an update: (Afro-IP), South African music industry blames pirates for falling sales of local artists: (Afro-IP), Plaintiff obtains interlocutory relief in patent case Sanitam Services Limited v Bins (Nairobi) Services Limited: (Afro-IP), South Africa – new patent judgments: Buckman Laboratories v Bromine Compounds; Northpark Trading 3 (Pty) Ltd v Ausplow (Pty) Ltd:… [read post]
18 Jul 2008, 8:34 am
: (GenericsWeb), Eularis analyses most effective generics defence strategies with new pharmaceutical industry report: (GenericsWeb), WIPO symposium to discuss life sciences multilateral environmental agreements: (Daily Dose of IP), Daiichi Sankyo and Ranbaxy confirm deal is binding and final, allay market rumour and speculation: (SmartBrief), Daiichi Ranbaxy takeover and the implications for the future of IP: (Spicy IP), Europe: Cancer Research Therapeutics’ RNAi patent… [read post]
22 Mar 2008, 2:00 am
: (IPBiz),US: Two remaining challenged WARF embryonic stem cell patents upheld in ex parte reexamination: (Holman's Biotech IP Blog), Pharma & Biotech - ProductsAricept (Donepezil) – USV wins appeal against USPTO decision: (Spicy IP),Celerex (Celecoxib) – CAFC decision in Celebrex patents dispute between Pfizer and Teva will cut patent term by one and a half years: (Patent Baristas), Inersan – Ranbaxy in-licenses Inersan to CD Pharma to market in… [read post]
20 Jun 2008, 8:07 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Associated Press – AP files seven DMCA takedowns against Drudge Retort blog over users linking to its stories: (The Trademark Blog), (Techdirt), (Out-Law), (Electronic Frontier Foundation), (IPKat), (The Trademark Blog), ECJ rules trade mark holders cannot stop honest comparative advertising: O2 Holdings Limited and O2 (UK)… [read post]
19 Sep 2008, 6:00 pm
: (Techdirt), (Techdirt), Pharma & Biotech Pharma & Biotech - General Biotech patent law: eleven key pending cases and future developments to watch: (Hal Wegner), (PatentDocs) Study by The Innovation Group highlights damaging intellectual property has been to biotech: (Techdirt), Drug regulatory agencies collaborate on counterfeits, new medical products: (Intellectual Property Watch), Canada: Health Canada releases summary report on industry consultations regarding… [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
18 Jan 2013, 2:06 pm
And if there’s another thing that’s not right, it’s imposing liability on a product manufacturer that didn’t make a cent (and probably was driven out of the market by) from the product that actually caused the injury in question.Nor is it very likely that this novel theory of “fraud/misrepresentation” liability can be limited to prescription drugs, whatever its intended scope. [read post]
27 Jun 2008, 10:04 am
Porsche AG: (Class 46), WIPO: Yell Limited v Yell.travel: domain name yell.travel to be transferred to Yell Limited: (Class 46), Some see rise in non-traditional trade marks; national registries not yet: (Intellectual Property Watch) Global - Patents Lower patentability standards – strategic responses: (IP Thinktank), IP Business Congress sees Finnish inventor become a millionaire: (IAM), Ron Slusky: Five prescriptions for effectively analysing an invention and… [read post]
30 May 2008, 9:09 am
Here is IP Think Tank’s weekly selection of top intellectual property news breaking in the blogosphere and internet. [read post]
18 Apr 2008, 2:00 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Ranbaxy and AstraZeneca reach agreement in Esomeprazole patent litigation: (SmartBrief), (IPBiz), (Spicy IP), (Profitability through Simplicity), (IP Law360), (Philip Brooks), (GenericsWeb), Cadbury loses Australian battle over exclusive use of colour purple for chocolate wrapping in its case against Darrell Lea: (Australian Trade Marks… [read post]
